Alex Davis

Thank you to #MelMcLaughlin for speaking openly about her lung cancer, thankfully detected early & treated w surgery Her story raises awareness of a widely misunderstood disease Wishing Mel a smooth recovery & return on @Channel7 soon shorturl.at/90JbB #LCSM #lungcancer

ESMO2025 DLL3 tour de force

Akeso reports Phase III HARMONi-A trial positive for survival. Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in #EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m) but OS was in question. Full results to be presented at #WCLC25. firstwordpharma.com/story/5992268

In a single-center study of NSCLC resections (2008-2020), long-term postop mortality dropped by almost 50% (HR 0.59; 95% CI 0.45–0.78) over 12 years, despite stable early post-op complications, possibly reflecting multiple contributing factors Read more: bit.ly/470IvJa

What is the role of Common Sense Oncology in the Western Pacific? sciencedirect.com/science/articl… @csoncol #cancercare #cancer #commonsenseoncology

city2surf25.grassrootz.com/thoracic-oncol… Hello all! After a great TOGA ASM I'm running the City2Surf to raise funds for Thoracic Cancer research. Thanks for all your support.

💡Starting out in thoracic oncology? The @IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders @JTOonline @OncoAlert #LCSM jto.org/article/S1556-…

I loved watching "ER" when I was a resident. But I can't watch "The Pitt". It's too close to home. I take the care of self & colleagues much more seriously these days. abc.net.au/news/2025-06-2…

@Mal_Itchins Great day!

An outstanding ACLS meeting getting wiser with this crew and more. Loved being involved

Grateful for the opportunity to present DB-1311/BNT324 (a novel B7H3 ADC) a Ph 1/2 study in patients with heavily pretreated CRPC (Abstract #5015) at #ASCO25 🎤 @Macquarie_Uni investigators: John Park @DSabanathan @HowardGurney @AlisonZhangMBBS Wei Yen Chan 🧵 1/7

Very comprehensive overview of where EGFR mutant lung cancer treatment is at.

Disheartening. Frustrating. Devastating. Patients unable to access immunotherapy via PBS for recurrent NSCLC due to once in a lifetime rule that is inconsistent w/ current standard of care. Communicating this to patients is hard. @MOGA_ORG pls keep advocating for change 🙏

Check out this recent proof-of-concept study looking at detection of #AntibodyDrugConjugate-induced interstitial lung disease using circulating cell-free DNA led by @AlbertGrinshpun and colleagues. 🔓pubmed.ncbi.nlm.nih.gov/39288654/ ✍️@AlbertGrinshpun @PTarantinoMD @stolaney1 @orifridlich @ESMO_Open

Sydney Swans in Grand Finals have strong Washington Generals vibes

@omalirp @MandersPeter As is tradition

In celebration of the upcoming #ACORD24 week, I’m bringing back this awesome post. Apparently I’m in my best bathrobe here.. It’s a fancy cardi made from Aussie wool and cute baubles thank you v much! 😂 @alexanderpdavis @MandersPeter

@omalirp @myESMO Enjoy the lounge

SYD 🇦🇺 ✈️ BCN 🇪🇸 26hrs but who’s counting when it’s for #ESMO24! @myESMO

Surprising results, stereotactic radiation plus anti-PD1 for stage 1-2 NSCLC, addition of immunotherapy does not confer benefit #lcsm merck.com/news/merck-pro…

Great discussion on drug reimbursement in Australia and particularly in thoracic oncology.

🌟 NSCLC Drug List 🫁🧬 A month late, but I have compiled a list of NSCLC drugs for 2024. Approved and unapproved are excluded. References are as follows. NCCN Ver 1. 2024 ESMO Guideline JLCS Guideline 2023